Medical robotics company SquareMind has raised $18 million to commercialize Swan, a robotic platform that performs automated full-body dermoscopic skin imaging for dermatology practices. The round was led by Sonder Capital, the venture fund co-founded by Intuitive Surgical founder Fred Moll, with participation from the Deeptech 2030 Fund managed by Bpifrance on behalf of the French government, Adamed Technology, Calm/Storm Ventures, Teampact Ventures, and several entrepreneurs. The capital will fund commercial, engineering, and customer support hiring ahead of Swan’s launch in the United States and Europe.
Swan acts as an augmented dermatoscope, capturing standardized images of the entire skin surface at a resolution typically reserved for close-up examination of individual moles. SquareMind says it is the first robot to perform this kind of automated full-body dermoscopic capture. During a session, the patient stands in a private exam room while a robotic arm moves around them, guided by visual and audio prompts, with image acquisition completed in minutes and without physical contact. The platform is paired with AI-based review software that helps track new or changing lesions over time, while clinical judgment remains with the physician.
The company is targeting a structural bottleneck in dermatology. Skin screening is the highest-volume procedure in the specialty, and waitlists in many markets now stretch into months as an aging population drives demand. SquareMind notes that roughly 80 percent of melanomas appear as new lesions rather than changes to existing ones, making consistent full-body documentation important for early detection but difficult to achieve under typical appointment time constraints.
The investment reflects continued capital flow into clinical robotics platforms designed to automate high-volume, documentation-heavy procedures rather than complex surgical interventions. Whether Swan can establish itself as a standard tool will depend on integration with clinical workflows, reimbursement pathways, and the ability of its imaging and AI-assisted review pipeline to produce outcomes that justify the equipment footprint in dermatology practices.
Disclaimer: RobotsBeat is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, Robotics, technology, software, and digital innovation sectors. These relationships do not influence RobotsBeat's editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.
